4 results about "Marker Antigens" patented technology

This application relates to a detection reagent, kit, and method that simultaneously improves sensitivity and broadens the detection range in competitive immunoassay. The reagent includes a detection antibody bound to luminescent microspheres that specifically binds to analyte molecules in the sample, and two sets of labeled antigens containing the same competing antigen and labeled molecules of different molecular weights bound to it. The competing antigen competes with the analyte molecule for binding to the detection antibody, and the affinity of the competing antigen for binding to the detection antibody is higher than that of the analyte molecule for binding to the detection antibody. The technical solution of this application, by using two sets of labeled antigens with different affinities, ensures that the labeled antigens that play a dominant role in samples with varying concentrations of analyte molecules differ. This is suitable for competitive immunoassay of small molecule antigens or haptens in both low-concentration and high-concentration samples, and can broaden the detection range while ensuring high functional sensitivity.

Proposed are a disease test kit for testing a disease on the basis of a body fluid and a disease testing method using the kit, wherein the disease test kit comprises: a sample pad to which a first blocking buffer is attached and into which a body fluid sample is introduced; a conjugate pad to which a second blocking buffer is attached and which binds the body fluid sample and a labeling antibody while storing the labeling antibody; a membrane pad for detecting a concentration of a labeling antigen in the body fluid sample bound to the labeling antibody; and a test strip including an absorption pad for absorbing and storing the sample that has passed through the membrane.

This invention relates to the field of biotechnology, specifically to a composite quality control product for gastric tumor markers and its preparation method. The composite quality control product comprises gastric tumor marker antigens and a quality control buffer solution. The quality control buffer solution comprises 1-10% protein protectant, 0.01-3% surfactant, 2-20% thickening antioxidant, 0.5-500 mg / L protease inhibitor, 0.01-3% metal ion chelating agent, and 0.5-10% buffer matrix. The gastric tumor marker antigens include G17, PGII, and CA72-4. This invention, by addressing the interactions between G17, PGII, and CA72-4 antigens, achieves composite quality control for eight gastric tumor markers. This covers the quality control of four conventional gastric tumor detection reagents (PGI, PGII, G17, and CA72-4) and four broad-spectrum tumor detection reagents (AFP, CEA, CA19-9, and CA242), which is of significant importance for clinical gastric tumor screening.

The application relates to a method for labeling an antigen protein with biotin, which comprises the following steps: (1) providing a ligase complex formed by a polypeptide chelated with Ni 2+ and a recombinant TurboID protein; (2) providing a recombinant antigen protein with a HisTag; and (3) reacting the recombinant antigen protein with the HisTag with biotin under the condition that the ligase complex, ATP and Mg 2+ exist to obtain the antigen protein labeled with biotin, wherein the amino acid sequence of the polypeptide in the step (1) is shown in SEQ ID NO: 1, and the amino acid sequence of the recombinant TurboID protein is shown in SEQ ID NO: 2. The method improves the labeling efficiency of the antigen protein labeled with biotin, improves the biotin utilization rate, and improves the positive detection rate of specific antibody detection in a clinical sample.